Naifa L. Busaidy, MD, FACP, FACE

home / authors / naifa-l-busaidy-md

Articles

endocrinologist

Novel Treatment Advances in Differentiated Thyroid Cancer

Lori J. Wirth, MD;Marcia Brose, MD, PhD, FASCO;Naifa L. Busaidy, MD, FACP, FACE;Maria E. Cabanillas, MD;Giuseppe Barbesino, MD
February 3rd 2022

An overview of therapies in the pipeline for differentiated thyroid cancer and their potential effect on clinical decision-making.

Read More

endocrinologist

Second-Line Treatment Approaches for DTC

Lori J. Wirth, MD;Naifa L. Busaidy, MD, FACP, FACE;Marcia Brose, MD, PhD, FASCO
February 3rd 2022

Naifa L. Busaidy, MD, FACP, FACE, recognizes the importance of reassessing patients prior to considering a second-line therapy for differentiated thyroid cancer.

Read More

thyroid cancer

Systemic Therapy Algorithms in DTC

Lori J. Wirth, MD;Marcia Brose, MD, PhD, FASCO;Maria E. Cabanillas, MD;Naifa L. Busaidy, MD, FACP, FACE
January 28th 2022

Considerations regarding approaches to sequencing therapies for differentiated thyroid cancer.

Read More

Dr. Busaidy on the Association Between THST and Improved Outcomes

Dr. Busaidy on the Association Between THST and Improved Outcomes

Naifa L. Busaidy, MD, FACP, FACE
October 31st 2014

Naifa L. Busaidy, MD, associate professor, MD Anderson Cancer Center, discusses the results of a cooperative study that investigated the association between long-term thyroid hormone suppression therapy and improved outcomes in patients.

Read More

Latest Updated Articles

Sarwish Rafiq, PhD
Published: July 9th 2024 | Updated: July 10th 2024
Dr Rafiq on Novel Strategies for CAR T-Cell Engineering in Solid Tumors
Jens Hoeppner, FAChirg, FACS, MD
Published: June 2nd 2024 | Updated: June 3rd 2024
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Published: July 25th 2024 | Updated: July 27th 2024
Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Published: July 25th 2024 | Updated: July 27th 2024
Dr Sabari on Barriers to Biomarker Testing in NSCLC
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Treatment Considerations and Patient Selection for CAR T-cell Therapy in R/R ALL
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Expert Insights on ZUMA-3 Data Updates: 4-Year Follow-up and Real World Data